Program

Keynote Session

Session Co-Chairpersons: Kohei Miyazono, University of Tokyo, Tokyo, Japan, and Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA
5:00 p.m.-6:30 p.m.

The biology of noncoding RNAs in cancer
Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA

Targeting essential growth drivers in human cancers
Hiroyuki Mano, Jichi Medical University, Tochigi, Japan; The University of Tokyo, Tokyo, Japan

Opening Reception

6:30 p.m.-8:00 p.m.

Breakfast/Mentoring Roundtables

7:00 a.m.-8:00 a.m.

Session 1: Cancer Genomes and Tumor Evolution

Sessuion Co-Chairpersons: William C. Hahn, Dana-Farber Cancer Institute, Boston, MA, USA, and Yoshio Miki, Tokyo Medical and Dental University, Tokyo, Japan
8:00 a.m.-9:30 a.m.

Survival of the fittest: Cancer genome evolution towards adaptation
Tatsuhiro Shibata, National Cancer Center Research Institute, Tokyo, Japan

Interrogating the architecture of cancer genomes
Peter J. Campbell, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Genome-wide analyses of rhabdomyosarcoma
Junko Takita, University of Tokyo, Tokyo, Japan

Break

9:30 a.m.-10:00 a.m.

Session 2: Circulating Tumor Cells and Other New Diagnostic Technologies

Session Co-Chairpersons: Okio Hino, Juntendo University School of Medicine, Tokyo, Japan, and Sean J. Morrison, UT Southwestern Medical School, Dallas, TX, USA
10:00 a.m.-11:30 a.m.

Bioengineering and clinical applications of circulating tumor cell chips
Shyamala Maheswaran, Massachusetts General Hospital, Charlestown, MA, USA

PLS3 expression in circulating blood is a good marker for colon cancer recurrence
Masaki Mori, Osaka University, Osaka, Japan

The clinical application of circulating tumor DNA
Luis A. Diaz, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Free Time

11:30 a.m.-3:30 p.m.

Session 3: Noncoding RNAs

Session Co-Chairpersons: Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA, and Hitoshi  Nakagama , National Cancer Center Research Institute, Tokyo, Japan
3:30 p.m.-5:00 p.m.

Senescence-associated microRNAs, a novel approach to tumor suppression
Hidetoshi Tahara, Hiroshima University, Hiroshima, Japan

microRNA reprogramming in cancer: Mechanisms and consequences
Joshua Mendell, UT Southwestern Medical Center, Dallas, TX, USA

Linking RNA to human health and disease
John L. Rinn, Harvard University, Cambridge, MA, USA

Poster Session A

5:00 p.m.-7:00 p.m.
View abstract titles and authors

Breakfast/Mentoring Roundtables

7:00 a.m.-8:00 a.m.

Session 4: DNA Damage Response

Session Co-Chairpersons: Fuyuki Ishikawa, Kyoto University, Kyoto, Japan, and Kevin M. Shannon, University of California, San Francisco, CA, USA
8:00 a.m.-10:00 a.m.

DNA damage response and cellular senescence in cancer
Eiji Hara, Japanese Foundation for Cancer Research, Tokyo, Japan

Modeling resistance to anticancer drugs
Jeffrey E. Settleman, Genentech, Inc., South San Francisco, CA, USA

Complex regulation of homologous recombination by E3 ligases
Shinichiro Nakada, Osaka University, Osaka, Japan

A systems approach to understanding and predicting therapeutic response
Joe W. Gray, Oregon Health & Science University's Knight Cancer Institute, Portland, OR, USA

Break

10:00 a.m.-10:30 a.m.

Session 5: Epigenetics and Cancer Cell States

Session Co-Chairpersons: Joshua Mendell, UT Southwestern Medical Center, Dallas, TX, USA, and Masahide Takahashi, Nagoya University Graduate School of Medicine, Nagoya, Japan
10:30 a.m.-12:00 p.m.

Epigenetic plasticity and its clinical implications in human neoplasia
Yutaka Kondo, Aichi Cancer Center, Nagoya, Japan

Human melanoma metastasis in NSG mice correlates with clinical outcome in patients
Sean J. Morrison, UT Southwestern Medical Center, Dallas, TX, USA

Dysregulation of noncoding RNA genes and its clinical application
Hiromu Suzuki, Sapporo Medical University, Sapporo, Japan

Free Time

12:00 p.m.-3:30 p.m.

Session 6: Cancer Progression and Metastasis

Session Co-Chairpersons: Motoharu Seiki, University of Tokyo Institute of Medical Science, Tokyo, Japan, and Lynda Chin, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
3:30 p.m.-5:00 p.m.

Molecular characterization of lung cancer progression
Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA

Hypoxia-inducible factor activity is an excellent marker for tumorigenesis and cancer progression
Shinae Kondoh, Tokyo Institute of Technology, Tokyo, Japan

The systemic environment as an important determinant of malignancy
Sandra S. McAllister, Brigham and Women's Hospital, Boston, MA, USA

Poster Session B

5:00 p.m.-7:00 p.m.
View abstract titles and authors

Breakfast/Mentoring Roundtables

7:00 a.m.-8:00 a.m.

Session 7: Tumor Microenvironment

Session Co-Chairpersons: Kevin M. Haigis, Massachusetts General Hospital, Charlestown, MA, USA, and Atsushi Ochiai, National Cancer Center, Hospital East, Kashiwa, Japan
8:00 a.m.-9:30 a.m.

Molecular targeting of tumor vasculature
Gou Young Koh, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea

Inflammation and cancer: Reprogramming the immune microenvironment as an anticancer therapeutic strategy
Lisa M. Coussens, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA

Mint3 promotes tumor malignancy in cancer and stromal cells
Takeharu Sakamoto, University of Tokyo, Institute of Medical Science, Tokyo, Japan

Break

9:30 a.m.-10:00 a.m.

Session 8: Cancer Immunology and Immunotherapy

Session Co-Chairpersons: Masao Seto, Aichi Cancer Center Research Institute, Nagoya, Japan, and Lisa M. Coussens, Oregon Health & Science University's Knight Cancer Institute, Portland, OR, USA
10:00 a.m.-11:30 a.m.

Immune checkpoint blockade in cancer therapy: New insights and opportunities
James P. Allison, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Impact of innate and acquired immune responses in adult T-cell leukemia
Mari Kannagi, Tokyo Medical and Dental University, Tokyo, Japan

microRNAs and myeloid-derived suppressor cells in tumor immune escape
Qingqing Wang, Zhejiang University School of Medicine, Hangzhou, China

Free Time

11:30 a.m.-3:30 p.m.

Session 9: Preclinical Models

Session Co-Chairpersons: Katerina A. Politi, Yale Cancer Center, New Haven, CT, USA, and Masanori Hatakeyama, University of Tokyo, Tokyo, Japan
3:30 p.m.-5:00 p.m.

GEM models in translational research
Lynda Chin, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Novel strategies for targeting cancer stem cells
Hideyuki Saya, Keio University, Tokyo, Japan

Contributions of the tumor microenvironment to chemoresistance
Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

Poster Session C

5:00 p.m.-7:00 p.m.
View abstract titles and authors

Breakfast/Mentoring Roundtables

7:00 a.m.-8:00 a.m.

Session 10: Signaling and Systems Biology

Session Co-Chairpersons: Seong-Jin Kim, CHA Cancer Institute, Seoul, Korea, and Cornelia M. Ulrich, German Cancer Research Center, Heidelberg, Germany
8:00 a.m.-9:00 a.m.

Genomic profiles of Asian-endemic cancers
Patrick Tan, Duke-NUS Graduate Medical School Singapore, Singapore

Statistical gene network analysis for understanding cancer heterogeneity
Seiya Imoto, University of Tokyo, Institute of Medical Science, Tokyo, Japan

Session 11: Cancer Prevention

Session Co-Chairpersons: Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA, and Johji Inazawa, Tokyo Medical & Dental University, Tokyo, Japan
9:00 a.m.-10:30 a.m.

Energy balance and inflammation in cancer prevention and prognosis
Cornelia M. Ulrich, German Cancer Research Center, Heidelberg, Germany

GWAS revealed the roles of gene-environmental interaction in carcinogenesis
Koichi Matsuda, University of Tokyo, Institute of Medical Science, Tokyo, Japan

Targeting cellular survival responses to replication stress as a novel approach for cancer prevention
Guang Peng, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Break

10:30 a.m.-11:00 a.m.

Session 12: Targeted Therapies and Resistance

Session Co-Chairpersons: Tomoki Naoe, Nagoya University Graduate School of Medicine, Aichi, Japan, and Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
11:00 a.m.-12:00 p.m.

TTF-1/NKX2-1: A double-edged sword in lung adenocarcinoma
Takashi Takahashi, Nagoya University, Nagoya, Japan

Biological mechanisms of resistance to targeted therapies
Katerina A. Politi, Yale Cancer Center, New Haven, CT, USA

Free Time

12:00 p.m.-4:30 p.m.

Poster Session D

4:30 p.m.-6:30 p.m.
View abstract titles and authors

Closing Banquet

7:00 p.m.-10:00 p.m.